sharon osbourne and elon musk have all publicly talked about taking ozempic or wigovy, and have had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps including tiktok. but it is not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining weight. chief executive lars fruergaard jorgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: they will tell you it is chronic treatment. my personal view is that patients are much different and there will be different avenues, so we will have to build a portfolio of interventions. francine: in this episode i travel to the firm's headquarters in copenhagen, denmark, and i ask about the global sensation, how he is navigating the company's meteoric rise and the sweeping changes they could bring across a range of industries. ♪ lars, thank you so much for being on bloomberg with